Venlafaxine ER in the treatment of MDD, GAD, SAD and Panic Disorder

Venlafaxine ER in the treatment of MDD, GAD, SAD, and Panic Disorder

A serotonin and norepinephrine reuptake inhibitor (SNRI) called Venlafaxine ER is prescribed to adults suffering from:

• Major Depressive Disorder (MDD)

• Generalized Anxiety Disorder (GAD) 

• Social Anxiety Disorder (SAD) 

• Panic Disorder (PD) 

Major Depressive Disorder (MDD):

Despite multiple adequate trials of antidepressant medications, up to 50% of MDD patients do not see enough improvement in their symptoms. The majority of these patients start treatment with selective serotonin reuptake inhibitors (SSRIs). Residual symptoms are common among patients who remit, and they are linked to worse psychosocial functioning and higher rates of relapse. Up until recently, the main distinctions between antidepressant medications were usually related to tolerability and safety. However in recent years, several studies have been conducted to assess potential variations in antidepressant classes' capacities to alleviate particular depressive symptoms. Due to their diverse ranges of activities, each group of medications in this class has the potential to be used in the treatment of MDD. 

Generalized Anxiety Disorder (GAD):

Roughly 6.8 million adult Americans suffer from GAD, with women affected at a rate roughly twice that of men. While it can start at any stage of life, the disorder progresses gradually, with childhood and middle age being the risk periods. A diagnosis of generalized anxiety disorder (GAD) is made when a person has excessive worry about a range of commonplace issues for at least six months. Five Even though people with GAD typically recognize that their anxiety is unwarranted given the circumstances, they still struggle to let go of their worries. Individuals find it difficult to focus, to unwind, and to startle easily. Frequently, they struggle to stay asleep or go to sleep at all. Anxiety is frequently accompanied by physical symptoms like headaches, exhaustion, aches and tension in the muscles, trouble swallowing, shaking, twitching, irritability, sweating, nausea, lightheadedness, frequent bathroom visits, dyspnea, and hot flashes.

Social Anxiety Disorder (SAD):

SAD, which affects about 5.3 million people annually in the US, is the most prevalent anxiety disorder. After alcohol abuse and depression, it is the third most prevalent mental illness. The hallmark of this disorder is a pronounced and enduring fear of social or performance situations where embarrassment could transpire. The disorder typically manifests in childhood or early adolescence and affects both men and women equally. There is some proof that genetic factors play a role. People with social anxiety disorder may also experience depression or other anxiety disorders, and if they attempt to self-medicate their anxiety, substance abuse may result.

Panic Disorder (PD):

A severe, persistent anxiety disorder, panic disorder is typified by frequent episodes of panic and the emergence of fear or anxiety about potential panic attacks in the future.

Anxiety disorders are thought to affect three to six million people annually, with women accounting for two-thirds of those affected. According to recent epidemiologic research, up to 15% of people in general may have sporadic panic episodes, while up to 3.5 percent may experience a lifetime case of complete panic disorder.

EFFICACY SCALES 

For MDD:

For a maximum of 12 weeks, 287 patients with MDD were randomly assigned to receive a placebo, venlafaxine ER 75 mg once daily, or venlafaxine IR 37.5 mg twice daily in a double-blind study. Venlafaxine's daily dosage may be increased to 150 mg if, following two weeks of treatment, the response is still insufficient. Venlafaxine in both dosage forms significantly outperformed a placebo starting in week two for the HAM-D and week three for the MADRS. For venlafaxine IR, significant improvement in CGI-S started at week six, and for venlafaxine ER, it started at week four. By week 12, Venlafaxine ER 150 mg outperformed venlafaxine IR in every efficacious measure.

For GAD:

In a double-blind trial, randomly assigned venlafaxine ER or placebo was given to 251 non-depressed outpatients with GAD who needed treatment for 28 weeks. Symptom response determined the appropriate daily dose of venlafaxine ER (75, 150, or 225 mg). In the venlafaxine ER group, response rates were at least 69% during weeks six through twenty-eight, while in the placebo group, they were between 42 and 46% (p<0.001). All primary efficacy measures, including the HAM-A, CGI-I, and CGI-S, were significantly improved by venlafaxine ER from week one or two through week 28 (p<0.001 for all comparisons to placebo), according to an evaluable-patient analysis. After sleeplessness and dry mouth, nausea was the most frequent treatment-emergent adverse event.

For SAD:

The effectiveness and safety of venlafaxine ER in the treatment of generalized SAD were investigated in a multicenter, double-blind trial. For 12 weeks, a total of 272 outpatients were randomized to receive either a placebo or a flexible dose of venlafaxine ER 75–225 mg daily. The LSAS at weeks four through twelve showed that venlafaxine ER was significantly more effective than placebo. During weeks four through twelve, the CGI-S and CGI-I both demonstrated that venlafaxine ER was substantially more effective than placebo. For the last eight weeks of the trial, the venlafaxine ER group experienced noticeably higher response rates.

For Panic Disorder:

361 adults with panic disorder were randomly assigned to receive either a placebo or venlafaxine ER 75–225 mg/day for a maximum of 10 weeks in a double-blind trial. Although there were fewer limited-symptom panic attacks in the venlafaxine ER group, there was no difference in the proportion of patients free from full-symptom panic attacks across treatment groups in the study.

Additionally, a lower mean frequency of panic attacks, better response and remission rates, and improvements in anticipatory anxiety, fear, and avoidance were linked to venlafaxine ER.

If EFFEXOR XR is not prescribed, do not use it for any condition. Give EFFEXOR XR only to those who are experiencing the same symptoms as you. It could hurt them. For information about EFFECTOR XR intended for healthcare professionals, speak with your pharmacist or healthcare provider.